구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | efgartigimod (Vyvgart, ARGX-113, Vyvgart Hytrulo, efgartigimod alfa-fcab) argenx·FcRn (neonatal Fc receptor) 48 trials·t½ ~3–4 days, but the IgG-lowering effect outlasts plasma exposure | nipocalimab (Imaavy, M281, nipocalimab-aahu) Johnson & Johnson / Janssen·FcRn 27 trials·t½ Supports q2w maintenance after loading |
|---|---|---|
Overview Program | Vyvgart (efgartigimod) | Imaavy (nipocalimab) |
Overview Company | argenx | Johnson & Johnson / Janssen |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | FcRn (neonatal Fc receptor) | FcRn |
Overview Indication | Generalized myasthenia gravis (AChR antibody positive), chronic inflammatory demyelinating polyneuropathy | Generalized myasthenia gravis (AChR or MuSK antibody-positive, age ≥12); warm autoimmune hemolytic anemia |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | Selective IgG reduction without touching albumin, other immunoglobulin classes, or complement — so infection risk stays much lower than with broad immunosuppression. | Continuous q2w maintenance after loading, MuSK coverage, and a wAIHA indication — not a CIDP or subcutaneous Hytrulo story. |
Positioning Known limitation | Seronegative or non-IgG-mediated disease does not respond; effect reverses on withdrawal. | Non-IgG-mediated disease and incomplete FcRn occupancy. |
Positioning Development positioning | First-in-class FcRn blocker, now competing with rozanolixizumab and nipocalimab. | FcRn class next to Vyvgart; split on cycle vs continuous dosing and on MuSK / wAIHA vs CIDP. |
MoA Mechanism | Binds FcRn and blocks IgG recycling, so pathogenic IgG autoantibodies are routed to lysosomal degradation; total IgG falls roughly 60–70% within a treatment cycle. | Occupies FcRn and blocks IgG recycling, lowering total and pathogenic IgG. Autoantibody titers fall while dosing continues and recover when it stops. |
MoA Biomarker | Total IgG and anti-AChR antibody titer; MG-ADL and QMG scores. | MG-ADL, QMG, AChR/MuSK serology; hemoglobin in wAIHA. |
PK/PD Half-life | ~3–4 days, but the IgG-lowering effect outlasts plasma exposure | Supports q2w maintenance after loading |
PK/PD Species | Cynomolgus monkey, Total IgG reduction, anti-AChR titer, MG-ADL change | Total IgG reduction, MG-ADL, hemoglobin |
PK/PD Animal (cat.) | Human, NHP | Human |
PK/PD Experiment | Pharmacokinetic | — |
Toxicology Species | Mouse, Rat | — |
Toxicology Major finding | Headache, respiratory and urinary tract infection, and injection-site reactions. IgG reduction is selective and reversible, so cumulative immunosuppression is limited compared with conventional agents. | Infection risk tracks the reversible IgG drop. Infusion reactions and hypersensitivity are labeled; this is not B-cell depletion. |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | Headache, respiratory and urinary tract infection, and injection-site reactions. IgG reduction is selective and reversible, so cumulative immunosuppression is limited compared with conventional agents. | Infection risk tracks the reversible IgG drop. Infusion reactions and hypersensitivity are labeled; this is not B-cell depletion. |
Clinical Selected reported efficacy | 68% | — |
Clinical Result source | ADAPT (NCT03669588) | Vivacity-MG3 (NCT04951622) / FDA label 2026 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | — |
Clinical Trial ref | NCT03669588 | NCT04951622 |
Preclinical Animal (cat.) | NHP | — |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | efgartigimod (Vyvgart, ARGX-113, Vyvgart Hytrulo, efgartigimod alfa-fcab) argenx·FcRn (neonatal Fc receptor) 48 trials·t½ ~3–4 days, but the IgG-lowering effect outlasts plasma exposure | nipocalimab (Imaavy, M281, nipocalimab-aahu) Johnson & Johnson / Janssen·FcRn 27 trials·t½ Supports q2w maintenance after loading |
|---|---|---|
Overview Program | Vyvgart (efgartigimod) | Imaavy (nipocalimab) |
Overview Company | argenx | Johnson & Johnson / Janssen |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | FcRn (neonatal Fc receptor) | FcRn |
Overview Indication | Generalized myasthenia gravis (AChR antibody positive), chronic inflammatory demyelinating polyneuropathy | Generalized myasthenia gravis (AChR or MuSK antibody-positive, age ≥12); warm autoimmune hemolytic anemia |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | Selective IgG reduction without touching albumin, other immunoglobulin classes, or complement — so infection risk stays much lower than with broad immunosuppression. | Continuous q2w maintenance after loading, MuSK coverage, and a wAIHA indication — not a CIDP or subcutaneous Hytrulo story. |
Positioning Known limitation | Seronegative or non-IgG-mediated disease does not respond; effect reverses on withdrawal. | Non-IgG-mediated disease and incomplete FcRn occupancy. |
Positioning Development positioning | First-in-class FcRn blocker, now competing with rozanolixizumab and nipocalimab. | FcRn class next to Vyvgart; split on cycle vs continuous dosing and on MuSK / wAIHA vs CIDP. |
MoA Mechanism | Binds FcRn and blocks IgG recycling, so pathogenic IgG autoantibodies are routed to lysosomal degradation; total IgG falls roughly 60–70% within a treatment cycle. | Occupies FcRn and blocks IgG recycling, lowering total and pathogenic IgG. Autoantibody titers fall while dosing continues and recover when it stops. |
MoA Biomarker | Total IgG and anti-AChR antibody titer; MG-ADL and QMG scores. | MG-ADL, QMG, AChR/MuSK serology; hemoglobin in wAIHA. |
PK/PD Half-life | ~3–4 days, but the IgG-lowering effect outlasts plasma exposure | Supports q2w maintenance after loading |
PK/PD Species | Cynomolgus monkey, Total IgG reduction, anti-AChR titer, MG-ADL change | Total IgG reduction, MG-ADL, hemoglobin |
PK/PD Animal (cat.) | Human, NHP | Human |
PK/PD Experiment | Pharmacokinetic | — |
Toxicology Species | Mouse, Rat | — |
Toxicology Major finding | Headache, respiratory and urinary tract infection, and injection-site reactions. IgG reduction is selective and reversible, so cumulative immunosuppression is limited compared with conventional agents. | Infection risk tracks the reversible IgG drop. Infusion reactions and hypersensitivity are labeled; this is not B-cell depletion. |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | Headache, respiratory and urinary tract infection, and injection-site reactions. IgG reduction is selective and reversible, so cumulative immunosuppression is limited compared with conventional agents. | Infection risk tracks the reversible IgG drop. Infusion reactions and hypersensitivity are labeled; this is not B-cell depletion. |
Clinical Selected reported efficacy | 68% | — |
Clinical Result source | ADAPT (NCT03669588) | Vivacity-MG3 (NCT04951622) / FDA label 2026 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | — |
Clinical Trial ref | NCT03669588 | NCT04951622 |
Preclinical Animal (cat.) | NHP | — |
추천 비교
추천 비교